Dr Lal Pathlabs' revenue growth was aided by a low base in Q3 while volume growth momentum continues. The street is a bit concerned about pricing pressure in an industry that has become so competitive now. In an interview to CNBC-TV18, Om Manchanda, CEO of Dr Lal Pathlabs discussed the company's Q3 performance.
Manchanda said that we have launched bundled tests in response to pricing pressure.
He further said that more competitive pricing leads to higher volume growth.
Talking about business, he said there are two parts to our business. One is consumer facing and second is B2B business which is high-end complex test and that will continue through our pick-up point expansion. Till last year we did about 5,000 pick-up points.
According to him, competitive intensity is going to be in the routine tests where the competition is with lot of labs but there is a large component of our business which depends on technology and it’s not available with everyone else.
On GST front, he said goods and services tax had adverse impact on cost structure.
For entire interview, watch accompanying video.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
